Table 1.
Main baseline characteristics of 86 HIV/AgHBs co-infected patients
| Variables | n |
|---|---|
| Male gender (%) | 83 (96. 5%) |
| Mean age (years) | 42 (± 7. 2) |
| Mode of HIV transmission | |
| -Men who have unprotected sex with men (%) | 64 (74. 4%) |
| - Exchange of needles among intravenous drug users (%) | 16 (18. 6%) |
| Clinical Variables | |
| - Advanced hepatic disease | 17 (19. 7%) |
| -Non adherence to treatment | 09 (10. 4%) |
| Treatment Given-HAART | |
| -Previous use of antiretroviral therapy | 81 (94. 1%) |
| -Patients under LAM + TDF combination therapy | 48 (56. 0%) |
| -Patients under LAM monotherapy | 31 (36. 0%) |
| -Previous use of either LAM or TDF | 81 (94. 1%) |
| - Previous use of LAM | 79 (91. 8%) |
| - Previous use of TDF | 48 (55. 8%) |
| -Time of use of TDF (months) | 4-21 |
| -Time of use of LAM (months) | 7-144 |
| -Laboratory Variables | |
| HBeAg positive | 42 (48. 9%) |
| HBV-DNA < 60 UI/mL | 50 (58. 1%) |
| HBV-DNA > 60 UI/mL | 34 (39. 5%) |
| HBV-DNA unknown | 02 (2. 32%) |
| HBV Genotype | |
| -genotype A | 21 |
| -genotype D | 05 |
| -genotype G | 05 |
| -genotype F | 03 |
| -CD4 cell count, median cells/μ1 | 545 (± 250) |
| -Baseline HIV RNA < 400 copies/mL | 73 (85%) |
| ALT level, normal | 54 (62. 7%) |
| - ALT level > 1. 5 × ULN† | 32 (37. 2%) |
| -Anti-HCV positive | 20 (23. 2%) |
| -Anti-HDV positive | 01 (1. 1%) |
ULN†-Upper Limit of Normality; LAM = lamivudine; TDF = tenofovir